Overview

Thrombophylaxis in Transurethral Surgery With Dalteparine

Status:
Completed

Trial end date:
2007-12-01

Target enrollment:
0

Participant gender:
All

Summary

The rationale for thrombophrophylaxis is well known. Without prophylaxis the incidence of objectivlely confirmed, hospital-acquired deep venous thrombosis is approximately 10% to 40% among medical or general surgical patients. In urology the prevalence is 15-40%. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy1 recommend against specific prophylaxis in patients undergoing transurethral procedures. Our study is the first double-blind, placebo-controlled study with Dalteparine as thrombophrophylaxis in transurethral surgery. The aim of the study is to proof that thrombophrophylaxis causes not more complications in transurethral surgery than without.

Phase:

N/A

Accepts Healthy Volunteers?

Details

Lead Sponsor:

University Hospital, Basel, Switzerland

Treatments:

Dalteparin
Heparin, Low-Molecular-Weight

Criteria

Inclusion Criteria:

- transurethral surgery

Exclusion Criteria:

- oral anticoagulation